| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Medicine (S.Y., S.E.), Mount Sinai Hospital and University of Toronto, and Department of Pathology (S.L.A.), University Health Network and University of Toronto, The Freeman Centre for Endocrine Oncology and The Ontario Cancer Institute, Toronto, Ontario, Canada M5G 2M9
Address all correspondence and requests for reprints to: Dr. Shereen Ezzat, Mount Sinai Hospital, 600 University Avenue, 437 Toronto, Ontario, Canada M5G 1X5. E-mail: sezzat{at}mtsinai.on.ca.
Fibroblast growth factor receptors (FGFRs) have been implicated in a multitude of endocrine cell hormonal and proliferative properties, and FGFR4 is differentially expressed in normal and neoplastic pituitary. We therefore examined the functionally important cis-DNA elements and multiprotein complexes implicated in the cooperative control of expression of the human FGFR4 gene in pituitary cells. Using deletional mapping, we defined a 214-bp (-115/+99) promoter that was functional in pituitary GH4 and PRL 235 cells. Overlapping 40- to 50-bp fragments of this minimal promoter were examined by EMSA. Interestingly, fragment C (-64/-26) included potential binding sites for the hematopoietic zinc finger-containing transcription factor Ikaros (Ik) flanked by binding sites for Sp and Ets-type factors. DNA binding by Ik, Sp, and Ets-like factors was confirmed by oligonucleotide competition and supershifting with specific antibodies. Transcriptional regulation of FGFR4 by Ik was demonstrated by cotransfection of Ik1 with or without Sp1 or Ets overexpression and by disruption of the Ik binding site. Although both Ets-1 and Sp1 overexpression stimulated promoter activity, mutation of the Ik-binding site completely eliminated the Ik1 effect. Specific Ik expression was identified by Western blotting of pituitary GH4 and PRL235 cells and localized in primary mouse hormone-producing anterior pituitary cells by immunocytochemistry. Our findings point to a new role for Ik outside the hematopoietic system and suggest a novel transcriptional contribution with Ets and Sp1 in regulation of FGFR4 in the pituitary.
This article has been cited by other articles:
 |
|
 |
|
  S. Loeper, S. L. Asa, and S. Ezzat Ikaros Modulates Cholesterol Uptake: A Link between Tumor Suppression and Differentiation Cancer Res., May 15, 2008; 68(10): 3715 - 3723. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Gurel, T. Ronni, S. Ho, J. Kuchar, K. J. Payne, C. W. Turk, and S. Dovat Recruitment of Ikaros to Pericentromeric Heterochromatin Is Regulated by Phosphorylation J. Biol. Chem., March 28, 2008; 283(13): 8291 - 8300. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Zhu, K. Lee, S. L. Asa, and S. Ezzat Epigenetic Silencing through DNA and Histone Methylation of Fibroblast Growth Factor Receptor 2 in Neoplastic Pituitary Cells Am. J. Pathol., May 1, 2007; 170(5): 1618 - 1628. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ezzat, X. Zhu, S. Loeper, S. Fischer, and S. L. Asa Tumor-Derived Ikaros 6 Acetylates the Bcl-XL Promoter to Up-Regulate a Survival Signal in Pituitary Cells Mol. Endocrinol., November 1, 2006; 20(11): 2976 - 2986. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ezzat, R. Mader, S. Fischer, S. Yu, C. Ackerley, and S. L. Asa An essential role for the hematopoietic transcription factor Ikaros in hypothalamic-pituitary-mediated somatic growth PNAS, February 14, 2006; 103(7): 2214 - 2219. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Yamamoto, T. Ito, A. Abe, F. Sido, K. Ino, A. Itakura, S. Mizutani, S. Dovat, S. Nomura, and F. Kikkawa Ikaros is expressed in human extravillous trophoblasts and involved in their migration and invasion Mol. Hum. Reprod., November 1, 2005; 11(11): 825 - 831. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ezzat, S. Yu, and S. L. Asa The Zinc Finger Ikaros Transcription Factor Regulates Pituitary Growth Hormone and Prolactin Gene Expression through Distinct Effects on Chromatin Accessibility Mol. Endocrinol., April 1, 2005; 19(4): 1004 - 1011. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Yu, L. Zheng, M. Ladanyi, S. L. Asa, and S. Ezzat Sp1-Mediated Transcriptional Control of Fibroblast Growth Factor Receptor 4 in Sarcomas of Skeletal Muscle Lineage Clin. Cancer Res., October 1, 2004; 10(19): 6750 - 6758. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Stankovic, M. Hubank, D. Cronin, G. S. Stewart, D. Fletcher, C. R. Bignell, A. J. Alvi, B. Austen, V. J. Weston, C. Fegan, et al. Microarray analysis reveals that TP53- and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses Blood, January 1, 2004; 103(1): 291 - 300. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ezzat, S. Yu, and S. L. Asa Ikaros Isoforms in Human Pituitary Tumors: Distinct Localization, Histone Acetylation, and Activation of the 5' Fibroblast Growth Factor Receptor-4 Promoter Am. J. Pathol., September 1, 2003; 163(3): 1177 - 1184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Brusic, R. S. Pillai, D. G. Silva, N. Petrovsky, RIKEN GER Group, GSL Members, and C. Schonbach Cytokine-Related Genes Identified From the RIKEN Full-Length Mouse cDNA Data Set Genome Res., June 1, 2003; 13(6): 1307 - 1317. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yu, S. L. Asa, R. J. Weigel, and S. Ezzat Pituitary Tumor AP-2{alpha} Recognizes a Cryptic Promoter in Intron 4 of Fibroblast Growth Factor Receptor 4 J. Biol. Chem., May 23, 2003; 278(22): 19597 - 19602. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Yu, L. Zheng, S. L. Asa, and S. Ezzat Fibroblast growth factor receptor 4 (FGFR4) mediates signaling to the prolactin but not the FGFR4 promoter Am J Physiol Endocrinol Metab, September 1, 2002; 283(3): E490 - E495. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
